Sublingual gland neoplasms: clinicopathological study of 8 cases

• Michał Gontarz ^[1] ; Marta Urbańska-Gąsiorowska ^[2] ; Jakub Bargiel ^[1] ; Krzysztof Gąsiorowski ^[1] ; Tomasz Marecik ^[1] ; Paweł Szczurowski ^[1] ; Jan Zapała ^[1] ; Grażyna Wyszyńska-Pawelec ^[1]
  1. [1] Department of Cranio-Maxillofacial Surgery, Jagiellonian University Medical College, Cracow, Poland. University Hospital, Cracow, Poland
  2. [2] Amethyst Radiotherapy Centre in Cracow, Poland
• Localización: Medicina oral, patología oral y cirugía bucal. Ed. inglesa, ISSN-e 1698-6946, Vol. 26, Nº. 5 (September), 2021
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Sublingual gland neoplasms are very rare and the majority of them are malignant. The aim of this study was to evaluate the clinical course, treatment, and outcomes of these uncommon neoplasms based on the authors’ experience and the recent literature.

    The medical charts of 8 patients with primary epithelial sublingual gland tumors treated between 1994 and 2020 were reviewed.

    Malignant tumors comprised 75% (6/8) of cases. Adenoid cystic carcinoma was the most common (50%, 3/6) and characterized by high risk of local recurrence and lung metastasis. Pleomorphic adenoma was the only representative of benign tumors with no evidence of local recurrence in follow up.

    Treatment of choice of sublingual gland tumors is surgery. However, due to the fact that adenoid cystic carcinoma is the most common malignancy with poor prognosis, surgical treatment should be combined with postoperative radiotherapy. Benign sublingual tumors are less common and treatment of choice in these cases is tumor resection together with sublingual gland.